Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - méthoxy polyéthylène glycol-epoetinum bêta - solution injectable dans une seringue préremplie - methoxy polyethylene glycol-epoetinum beta 360 µg, natrii sulfas anhydricus, natrii dihydrogenophosphas monohydricus, mannitolum, poloxamerum 188, acidum hydrochloridum q.s. ad ph, natrii hydroxidum q.s. ad ph, methioninum, aqua ad iniectabile q.s. ad solutionem pro 0.6 ml corresp. natrium 1.24 mg. - la stimulation de l'Érythropoïèse - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - levodopum, benserazidum - capsules - levodopum 50.00 mg, benserazidum 12.50 mg ut benserazidi hydrochloridum, mannitolum, cellulosum microcristallinum, talcum, povidonum k 90, magnesii stearas, kapselhülle: e 172 (nigrum), e 171, e 132, gelatina, drucktinte: lacca, propylenglycolum, ammoniae solutio 28 per centum, kalii hydroxidum, e 172 (nigrum), pro capsula. - morbus parkinson, des jambes sans repos-syndrom - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - levodopum, benserazidum - capsules - levodopum 100.0 mg, benserazidum 25.0 mg ut benserazidi hydrochloridum, cellulosum microcristallinum, talcum, povidonum k 90, magnesii stearas, kapselhülle: e 172 (rubrum), e 171, e 132, gelatina, drucktinte: lacca, propylenglycolum, ammoniae solutio 28 per centum, kalii hydroxidum, e 172 (nigrum), pro capsula. - morbus parkinson, des jambes sans repos-syndrom - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - levodopum, benserazidum - capsules - levodopum 200.0 mg, benserazidum 50.0 mg ut benserazidi hydrochloridum, cellulosum microcristallinum, talcum, povidonum k 90, magnesii stearas, kapselhülle: e 172 (rubrum), e 172 (flavum), e 171, e 132, gelatina, drucktinte: lacca, propylenglycolum, ammoniae solutio 28 per centum, kalii hydroxidum, e 172 (nigrum), pro capsula. - morbus parkinson, des jambes sans repos-syndrom - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - levodopum, benserazidum - comprimés - levodopum 200.00 mg, benserazidum 50.00 mg ut benserazidi hydrochloridum, mannitolum, calcii hydrogenophosphas, cellulosum microcristallinum, amylum pregelificatum, crospovidonum, ethylcellulosum, e 172 (rubrum), silica colloidalis anhydrica, natrii docusas corresp. natrium 0.01 mg, magnesii stearas, pro compresso. - morbus parkinson, des jambes sans repos-syndrom - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - levodopum, benserazidum - comprimés - levodopum 100.00 mg, benserazidum 25.00 mg ut benserazidi hydrochloridum, mannitolum, calcii hydrogenophosphas, cellulosum microcristallinum, amylum pregelificatum, crospovidonum, ethylcellulosum, e 172 (rubrum), silica colloidalis anhydrica, natrii docusas corresp. natrium 0.005 mg, magnesii stearas, pro compresso. - morbus parkinson, des jambes sans repos-syndrom - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - levodopum, benserazidum - comprimés pour suspension buvable - levodopum 50.00 mg, benserazidum 12.50 mg ut benserazidi hydrochloridum, acidum citricum, amylum pregelificatum, cellulosum microcristallinum, magnesii stearas pro compresso. - morbus parkinson, des jambes sans repos-syndrom - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - levodopum, benserazidum - comprimés pour suspension buvable - levodopum 100.00 mg, benserazidum 25.00 mg ut benserazidi hydrochloridum, acidum citricum, amylum pregelificatum, cellulosum microcristallinum, magnesii stearas pro compresso. - morbus parkinson, des jambes sans repos-syndrom - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - levodopum, benserazidum - comprimés - levodopum 200.000 mg, benserazidum 50.000 mg ut benserazidi hydrochloridum, hypromellosum, mannitolum, e 172 (rubrum), povidonum k 30, magnesii stearas, silica colloidalis hydrica, ricini oleum hydrogenatum, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 2.9 mg, pro compresso. - morbus parkinson, des jambes sans repos-syndrom - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - enfuvirtidum - solution injectable - praeparatio cryodesiccata: enfuvirtidum 90 mg, natrii carbonas, mannitolum, natrii hydroxidum aut acidum hydrochloridum, pro vitro corresp. natrium 1.037 mg. solvens: aqua ad iniectabile pro vitro. - les infections à vih - synthetika